UK: Is Precision Medicine Hitting The Target?

Last Updated: 20 September 2016
Article by Amen Sanghera

I am delighted to use this week's blog to introduce one of the Centre's new analysts, Amen Sanghera. During his MSc studies in Nanotechnology and Regenerative Medicine (2013 -14) Amen was fortunate to gain first-hand exposure to the potential that precision medicine (PM) can have for patients. His blog explores this potential and considers the extent to which key stakeholders (payers, providers, physicians and patients) are ready to embrace the move towards precision medicine.

What is precision medicine?

PM is an emerging approach for treatment and prevention that takes into account a person's genetics, environment and lifestyle. It allows doctors and researchers to predict more accurately which strategies for a particular disease will work in which groups of people. It is in contrast to the traditional "one-size-fits-all" approach in which disease treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.

While the term PM is relatively new, the concept has been around for many years. However, it is only in recent times that we have seen the first tentative steps towards turning the PM rhetoric into reality. Genetic profiling and accompanying diagnostic testing currently form the fundamental driving force in bringing precision therapies to clinical practice. These breakthroughs have allowed providers and physicians to understand diseases at a molecular level and specify a means for accurate diagnosis and the development of targeted therapies.

How has the industry's perspective changed?

PM was initially met with scepticism by the pharmaceutical industry, particularly from a business point of view. The industry saw spending resources developing therapies that treat specific sub-segments of patient populations as reducing the potential size of the addressable market. However, this view has changed over the past decade, thanks to the implementation of favourable regulatory policies and incorporation strategies in major markets. As a result, the percentage of PM drug approvals in the US increased from 22 per cent in 2014 to 29 per cent in 20151 and the number of PM products available on the market increased from 13 in 2006 to 113 in 2014.2

Oncology leading the way

Oncology is one area in which PM is making significant inroads, with the US regulators giving priority to PM for oncology treatment.3 Indeed, in 2015, 36 per cent of newly approved oncology drugs were PMs.4 The increased use of PM in oncology is partly due to being able to demonstrate its clinical advantages more readily in cancer treatment compared to other therapy areas, such as autoimmune diseases.

Slow adoption

Clinical adoption of PM outside of oncology is slow, due to a number of challenges that have deterred key stakeholders from embracing the prescribing of PM therapies. These include:

  • scientific and technical challenges such as overcoming clinical hurdles (demonstrating efficacy), developing therapies for a wider array of diseases, finding the right biomarkers, and a better comprehension of the benefits of molecular therapies amongst payers
  • economic challenges which include incentive systems that are often slow to adapt to new trends in healthcare and are counterproductive in enabling innovation to succeed
  • regulatory roadblocks that have made the approval process for PM unclear and convoluted, particularly in markets outside of the US such as the UK and Germany
  • operational challenges which includes the need for healthcare infrastructures capabilities and technologies that support the standardised collection and safe storage of data, enable faster diagnostic testing; and the training of medical personnel on understanding diagnosis and precision treatments.

Economic considerations of precision medicine

There are also long term economical concerns on how the business model for PM will play out. Technologies to sequence large amounts of genetic information remain expensive (although reducing). The cost of pharmaceutical research and development is inherently high and potential returns on investment are constrained by the smaller size of the treatable population, leading to high prescribing costs. Furthermore, there is the cost of investment in the capability and capacity to obtain precision diagnostics and deliver personalised treatment when compared to traditional approaches that may not benefit a proportion of the population treated.4 On the other hand PM could lead to a drop in research and development costs as the rates of failure and time taken to prove efficacy reduce, ultimately lowering costs for patients.5 We are at a tipping point where the evidence to underpin the business model is only now emerging. Realising the potential of PM will need to be underpinned by more precise economics.

What will drive change?

In order for these issues to be resolved, a more concerted effort is needed to address the concerns of each of the key stakeholders. Specifically more data is required to understand the clinical and long term economic benefits of PM. As more and more leading institutions begin adopting PM therapies, best practice methodologies should begin to emerge thereby increasing adoption. This in turn should improve patient access to PM at both lower clinical and economical risk than is currently the case.

Healthcare remains an industry in which innovation outpaces regulatory policy, reimbursement processes and clinical reform. PM has only just begun to scratch the surface of its potential. Over the last decade we have seen how the perspective of industry has changed and with the current penetration of PM in oncology, we are seeing key stakeholder views also evolve. Ultimately, it is long term data (clinical and economical) that will help shape the development and adoption of PM. Whether that evidence base is strong enough to promote implementation of PM outside of oncology, only time will tell. However, with the implementation of multiple government backed programmes over the last five years, such as the UK's "100,000 genomes project",6 key enablers for change are now in place.

Footnotes

1 http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/2014-fda-approvals-personalized-medicine2.pdf
2 http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/2015_Progress_Report_PM_at_FDA.pdf
3 http://www.mdpi.com/2075-4426/6/2/15/htm#B7-jpm-06-00015
4 https://ghr.nlm.nih.gov/primer/precisionmedicine/challenges
5 https://scrip.pharmamedtechbi.com/SC064596/Economics-Of-Precision-Medicine-Will-It-Lower-Drug-Costs
6 https://www.england.nhs.uk/wp-content/uploads/2015/09/item5-board-29-09-15.pdf

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions